2014
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development
Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics In Biosciences 2014, 8: 99-128. PMID: 27617040, PMCID: PMC5014437, DOI: 10.1007/s12561-014-9124-2.Peer-Reviewed Original ResearchBiomarker profilesMD Anderson Cancer CenterPatient's biomarker profileChoice of treatmentAnderson Cancer CenterTreatment effectsMore effective treatmentsOverall treatment effectTargeted therapy developmentMore patientsCancer CenterLung cancerPredictive biomarkersPredictive markerAdaptive randomization designIndividual patientsEffective treatmentBetter outcomesTreatment efficacyPatientsBayesian adaptive designRelevant biomarkersKnown markerTherapy developmentBest treatment
2012
L4.1 Evolution of Battle Trials at Md Anderson Cancer Center
Hong W, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center. Annals Of Oncology 2012, 23: v7. DOI: 10.1016/s0923-7534(20)31272-2.Peer-Reviewed Original ResearchNational Lung Screening TrialLung cancerBATTLE TrialHigh riskLow-dose helical computed tomographyLung Cancer Elimination (BATTLE) trialMolecular driversMD Anderson Cancer CenterUntreated lung cancerAdvanced lung cancerFive-year survivalAdvanced cancer settingLung cancer patientsCore needle biopsyLung cancer developmentNovel trial designsAnderson Cancer CenterPatient treatment selectionFresh tumor biopsiesHelical computed tomographyEarly-stage cancerNumber one causeOptimal drug combinationsRefractory patientsPrevention setting
2008
Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer
Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 351-357. PMID: 18379352, DOI: 10.1097/jto.0b013e318168c7e9.Peer-Reviewed Original ResearchConceptsLung cancer patientsTumor cavitationCancer patientsAntiangiogenesis agentsAdverse eventsLung cancerMD Anderson Cancer CenterChest imaging findingsProgression-free survivalAdditional adverse eventsSquamous cell histologySquamous cell tumorsAnderson Cancer CenterCavitary tumorsPrevious chemotherapyCell histologyOverall survivalClinical outcomesImaging findingsCancer CenterCell tumorsTumor locationMedical recordsClinical dataClinical significance
2007
Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients
Onn A, Martinez C, Herbst R, Riddle J, Blumenschein G, Stewart D, Marom E. Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients. Journal Of Clinical Oncology 2007, 25: 18034-18034. DOI: 10.1200/jco.2007.25.18_suppl.18034.Peer-Reviewed Original ResearchTumor cavitationLung cancer patientsAntiangiogenic agentsCancer patientsAngiogenesis inhibitorsNon-small cell lung cancer patientsClinical implicationsMedian progression-free survivalCell lung cancer patientsMD Anderson Cancer CenterProgression-free survivalSoft tissue densityAnderson Cancer CenterPrevious chemotherapyStable diseaseAdverse eventsNSCLC patientsAdvanced cancerCancer CenterNSCLC casesLung cancerPrimary tumorMedical recordsSubsegmental arteriesClinical data